Wei, Penghui
Jia, Min
Kong, Xiangyi
Lyu, Wenyuan
Feng, Hao
Sun, Xinyi
Li, Jianjun
Yang, Jian-jun
Funding for this research was provided by:
National Natural Science Foundation of China (82101255, 81971020)
Natural Science Foundation of Shandong Province (ZR2020QH291)
Zhongyuan Science, and Technology Innovation Leadership Program of Henan Province (ZYYCYU202012030)
Qingdao Key Health Discipline Development Fund (QDZDZK-2022094)
Qingdao Outstanding Health Professional Development Fund (2022)
Article History
Received: 12 April 2023
Accepted: 14 September 2023
First Online: 21 September 2023
Declarations
:
: All efforts were made to minimize the number and suffering of the animals used in the study. The animal experimental protocol was approved by the Animal Care and Use Committee of Qilu Hospital (Qingdao), Shandong University (Approved project: hUC-MSCs ameliorate PND by inhibiting microglia-mediated neuroinflammatory responses via NOD-, LRR- and pyrin domain-containing 3 inflammasome, approval number: KYDWLL-202221, Date of approval: Jan 21st, 2022) and was conducted in accordance with the guidelines for experimental animal use established by the Institutional Animal Care and Use Committee of Shandong University. An umbilical cord for hUC-MSC isolation and culture was obtained at Qilu hospital from a full-term healthy infant delivered after a cesarean section, whose mother had signed an informed consent form and the procedure was approved by the Qilu hospital’s human research ethics committee (approved project: Applications of MSCs in inflammation-related chronic diseases, approval number: KYLL-2021(KS)-086, Date of approval: Feb 20st, 2021).
: Not Applicable.
: The authors declare that they have no conflicts of interest.